West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) Free cash flow margin
West Pharmaceutical Services, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 13.1%, down 2.1 percentage points from fiscal 2025 (15.3%). Over the past ten years it has ranged from 3.26% (fiscal 2016) to 15.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Instruments & Supplies industry median of 1.08% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 15.3% | 5.70 |
| FY2024 | 9.55% | (4.50) |
| FY2023 | 14.1% | (1.17) |
| FY2022 | 15.2% | 3.54 |
| FY2021 | 11.7% | (2.21) |
| FY2020 | 13.9% | 0.80 |
| FY2019 | 13.1% | 2.38 |
| FY2018 | 10.7% | 2.42 |
| FY2017 | 8.29% | 5.03 |
| FY2016 | 3.26% | (2.51) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RMD ResMed Inc. compare | 28.8% |
| COO The Cooper Companies, Inc. compare | 16.0% |
| ALC Alcon compare | 14.7% |
| BDX Becton, Dickinson and Company compare | 14.3% |
| RGEN Repligen Corporation compare | 14.1% |
| WST West Pharmaceutical Services, Inc. | 13.1% |
| MDLN Medline Inc. compare | 7.75% |
| BAX Baxter International Inc. compare | 7.11% |
| SOLV Solventum Corporation compare | −1.42% |
| Medical Instruments & Supplies industry median | 1.08% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement